Proteomics International Laboratories Ltd 2022 AR2
The report highlights Proteomics International Laboratories Ltd's achievements for the fiscal year ended June 30, 2022, focusing on the commercialization of its flagship PromarkerD test for diabetic kidney disease and the expansion of its diagnostics pipeline. Key milestones include a collaborative study with Janssen showing positive treatment effects, expanding the PromarkerD distribution network to Britain, and filing a submission to the Australian Therapeutic Goods Administration. The company also completed a clinical validation study for endometriosis and secured a worldwide license for oesophageal cancer biomarkers. Financially, analytical services revenue grew by 14% to $1.49 million, while the company continued to invest heavily in research and development.
Company: Proteomics International Laboratories Ltd
Sector: Professional & technical services
Country: Australia
Year: 2022
Type: AR2
Pages: 45
Back to company
Proteomics International Laboratories Ltd
Annual Report
The report highlights Proteomics International Laboratories Ltd's achievements for the fiscal year ended June 30, 2022, focusing on the commercialization of its flagship PromarkerD test for diabetic kidney disease and the expansion of its diagnostics pipeline. Key milestones include a collaborative study with Janssen showing positive treatment effects, expanding the PromarkerD distribution network to Britain, and filing a submission to the Australian Therapeutic Goods Administration. The company also completed a clinical validation study for endometriosis and secured a worldwide license for oesophageal cancer biomarkers. Financially, analytical services revenue grew by 14% to $1.49 million, while the company continued to invest heavily in research and development.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2022
Reporting Period
Jul 1, 2021 - Jun 30, 2022
Fiscal Year
2022
Type
Annual Report with Sustainability Disclosures
Language
English
Pages
File Size
Standards & Assurance
Materiality Assessment
ESG Data?Experimental: AI-extracted data, may contain inaccuracies
Women on Board
Women in Management